Halozyme Therapeutics, Inc. (HALO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Halozyme Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Halozyme Therapeutics, Inc. (HALO) has returned -3.97% so far this year and 1.29% over the past 12 months. Looking at the last ten years, HALO has achieved an annualized return of 20.82%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Mar 16, 2004, HALO's average daily return is +0.12%, while the average monthly return is +2.47%. At this rate, your investment would double in approximately 2.4 years.

Historically, 54% of months were positive and 46% were negative. The best month was Dec 2006 with a return of +178.6%, while the worst month was Jan 2016 at -49.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.

On a daily basis, HALO closed higher 49% of trading days. The best single day was Dec 6, 2006 with a return of +59.6%, while the worst single day was Aug 2, 2012 at -49.8%.

Halozyme Therapeutics, Inc. has an annualized alpha of 19.39%, beta of 1.19, and R² of 0.15 versus S&P 500 Index. Calculated based on daily prices since March 17, 2004.

• This stock captured 159.73% of S&P 500 Index gains and 130.35% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.15 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HALO ranks 40 for risk / return — below 40% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Halozyme Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Halozyme Therapeutics, Inc. was 74.26%, occurring on Dec 4, 2008. Recovery took 795 trading sessions.

The current Halozyme Therapeutics, Inc. drawdown is 20.44%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Halozyme Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Halozyme Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.